The U.S. Food and Drug supervision approved a single shared Risk appraisal and amends setup (REMS) for the transmucosal immediate-release fentanyl (TIRF) products. This new shared system will replace the separate REMS and allow prescribers and pharmacies to enroll into just one system, easing the burden on the health care system. TIRF medicines, which include the brand-name drugs Abstral, Actiq, Fentora, Lazanda, and Onsolis, are stupefacient pain medicines called opioids used to manage pain in adults with cancer who routinely take other opioid pain medicines around-the-clock...

More: - Read More